ViiV Healthcare announces positive result in TANGO Phase 3 study
Category: #health  By Paroma Bhattacharya  Date: 2019-07-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

ViiV Healthcare announces positive result in TANGO Phase 3 study

ViiV Healthcare Limited, a pharmaceutical company specializing in HIV treatment, recently announced positive results from Phase 3 TANGO study.

The study was conducted to assess viral suppression in adults with HIV1 with a 2 drug regimen of dolutegravir in combination with lamivudine. Patients were chosen on the basis that they had previously maintained viral suppression for at least 6 months on a TAF (Tenofovir Alafenamide Fumarate) containing 3 drug regimens. It aimed to verify whether the same could be achieved through the 2 drug regimen. The results from the study will be presented at the 10th IAS Conference on HIV Science, in Mexico City.

Based on a proportion of participants with plasma HIV 1 RNA≥50 copies c/ml, using the Food & Drug Administration Snapshot algorithm at 48th week, the study has reportedly reached its primary end-point for non-inferiority. None of the patients developed treatment resistance in the dolutegravir and lamivudine arm of the study nor did they meet confirmed virologic withdrawal criteria. The safety results for the 2 drug regimen of dolutegravir in combination with lamivudine were consistent with the product labelling for the medicines.

Kimberly Smith, MD and Head of Global Research & Medical Strategy at ViiV Healthcare Limited, was reportedly quoted saying that the company has been developing the TANGO study to reduce the number of medicines in HIV treatment regimen to maintain viral suppression. The 48th week data from the final study proves that patients, who are already on treatment can maintain viral suppression if they switch from a 3 drug tenofovir alafenamide fumarate -containing regimen to a 2 drug regimen of dolutegravir in combination with lamivudine.

As per credible sources, the single-pill, 2-drug dolutegravir in combination with lamivudine, was authorized in U.S. earlier this year for the treatment of HIV-1 infection in adults with no ARV (antiretroviral) treatment history & with no known resistance to either lamivudine or dolutegravir. It was also authorized in Europe recently for the treatment of HIV 1 infection in adults & adolescents above 12 years, with minimum weight of 40 kg, with no known or suspected resistance to the INI (integrase inhibitor) class, or lamivudine.

Source credit: https://www.viivhealthcare.com/en-gb/media/press-releases/2019/july/viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint/



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Walmart to roll out Delivery Unlimited grocery service across U.S.
Walmart to roll out Delivery Unlimited grocery service across U.S.
By Paroma Bhattacharya

Walmart, the retail giant, recently announced that it is rolling out a new Delivery Unlimited grocery service in 1,400 Walmart stores across U.S. Reportedly, the subscription membership will charge an annual fee of USD...

Amazon gears up for Diwali sale, expands next-day delivery service
Amazon gears up for Diwali sale, expands next-day delivery service
By Paroma Bhattacharya

The firm has increased its overall reach for large appliances to 14,000 pin codes and next-day delivery facilities to over 650 cities.

Amazon.in, the Indian divisio...

4BIO Capital intends to take gene and cell therapies mainstream
4BIO Capital intends to take gene and cell therapies mainstream
By Paroma Bhattacharya

The venture capitalist firm has secured an investment of $50 million and is expecting to gather an investment of up to $150 million till 2020.

4BIO Capital, a Londo...